Cargando…
Prolonged release melatonin for improving sleep in totally blind subjects: a pilot placebo-controlled multicenter trial
INTRODUCTION: Melatonin, secreted by the pineal gland during the night phase, is a regulator of the biological clock and sleep tendency. Totally blind subjects frequently report severe, periodic sleep problems, with 50%–75% of cases displaying non-24-hour sleep–wake disorder (N24HSWD) due to inabili...
Autores principales: | Roth, Thomas, Nir, Tali, Zisapel, Nava |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319556/ https://www.ncbi.nlm.nih.gov/pubmed/25678831 http://dx.doi.org/10.2147/NSS.S71838 |
Ejemplares similares
-
Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial
por: Wade, Alan G, et al.
Publicado: (2014) -
Prolonged-release melatonin for insomnia – an open-label long-term study of efficacy, safety, and withdrawal
por: Lemoine, Patrick, et al.
Publicado: (2011) -
Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety
por: Wade, Alan G, et al.
Publicado: (2010) -
Sleep, Growth, and Puberty After 2 Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder
por: Malow, Beth A., et al.
Publicado: (2020) -
Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials
por: Lemoine, Patrick, et al.
Publicado: (2012)